

³⁵**Abstract**

³⁶**Aims:** This study explores the correlation between site-specific 37 methylation levels of the KCNJ11 promoter and type 2 diabetes mellitus ³⁸(T2DM), analyzing potential molecular mechanisms.

³⁹**Methods:** Thirty patients newly diagnosed with T2DM and 30 healthy 40 controls were selected to determine the CpG methylation levels in the 41 promoter region of the KCNJ11 gene using the bisulfite assay. The online 42 software JASPAR was used to predict transcription factors binding to 43 differentially methylated sites. Key transcription factors were further validated 44 through quantitative PCR (q-PCR) and chromatin immunoprecipitation 45 followed by PCR (ChIP-PCR).

⁴⁶**Results:** Methylation at multiple CpG sites within the KCNJ11 gene 47 promoter was significantly reduced in newly diagnosed T2DM patients 48 compared to healthy individuals. The methylation status of CpG-471, a site 49 crucial for the binding of the transcription factor TCF12, emerged as 50 potentially influential in T2DM pathogenesis. This reduction in methylation at ⁵¹CpG-471 may enhance TCF12 binding, thereby altering KCNJ11 expression.

⁵²**Conclusion:** Hypomethylation of specific CpG sites in the promoter region 53 of the KCNJ11 gene in patients with incipient T2DM potentially contributes to 54 the disease's pathogenesis. This hypomethylation enhances the 55 transcriptional activity of TCF12, which binds to these sites, possibly 56 influencing regulatory pathways involved in pancreatic beta-cell function.

⁵⁷**Keywords**

⁵⁸Type 2 diabetes; DNA methylation; KCNJ11 gene; TCF12 transcription factor

⁶⁰**1. Introduction**

⁶¹Type 2 diabetes mellitus (T2DM) is a complex polygenic disease[1], primarily 62 driven by insulin resistance and inadequate insulin production from β cells[2]. ⁶³According to the updated version of the International Diabetes Federation ⁶⁴(IDF) Diabetes Atlas, more than 500 million patients worldwide have diabetes, ⁶⁵and this number is expected to increase by 20% by 2030 and 46% by 2045[3]. ⁶⁶China has the highest prevalence of diabetes and prediabetes, with an 67 estimated 10.9% of Chinese adults diagnosed with diabetes and 35.7% with 68 prediabetes[4]. Due to the significant increase in the incidence of T2DM and ⁶⁹its concomitant acute and chronic complications, it is an important cause of 70 patient death and increased healthcare costs, which brings a huge economic ⁷¹burden to the society, and there is an urgent need to actively intervene in the 72 treatment of T2DM from the etiologic and early prevention perspectives[5, 6]. ⁷³The etiology of T2DM is complex, resulting from a combination of genetic and ⁷⁴environmental factors[7]. An important area of current research is the search 75 for reliable, sensitive and easily accessible biomarkers for T2DM. In this 76 context, a growing number of studies[8-13]suggest that genetic and 77 epigenetic mechanisms together play an important role in the pathogenesis of 78 T2DM patients.

⁸⁰Differential variability in DNA methylation, often indicative of epigenetic 81 dysregulation, is associated with various phenotypes, pathologies, and 82 adverse environments[9]. Initial epigenetic studies in pancreatic islets and 83 skeletal muscle of T2DM patients identified altered methylation 84 patterns[14].Recent genome-wide DNA methylation studies have confirmed 85 these findings, revealing altered methylation levels in diabetes-associated 86 genes like TCF7L2[15], PDX-1[16], CDKN1A[17], FTO[18], and 87 PPARGC1A[19], with changes in their promoter regions correlating with

88 diabetes risk and severity. Additionally, the KCNJ11 gene, encoding the Kir6.2 89 subunit of the ATP-sensitive K+ channel crucial for insulin secretion, has been ⁹⁰linked to T2DM development through both genetic mutations and methylation 91 changes[20-28]. Research has shown that methylation patterns of KCNJ11 92 vary by geography and ethnicity, with significant differences observed 93 between Indian and European T2DM populations[29]. These findings highlight ⁹⁴the complex interplay of genetic and epigenetic factors in T2DM, emphasizing 95 the potential of methylation studies in understanding and addressing this 96 widespread disease.

97

⁹⁸While genome-wide association studies have extensively documented ⁹⁹changes in methylation patterns, few have focused on methylation at specific ¹⁰⁰sites. Therefore, our study aims to investigate the correlation between specific ¹⁰¹methylation sites in the KCNJ11 gene promoter and the onset of Type 2 102 Diabetes Mellitus (T2DM), as well as how these modifications affect gene 103 expression through transcription factor regulation. Supporting literature 104 suggests that age-related methylation changes detectable in blood could 105 serve as biomarkers for T2DM[30-32]. To this end, we selected 30 patients 106 newly diagnosed with T2DM (20 men and 10 women), average age 57.0 \pm ¹⁰⁷13.1 years. We also recruited 30 matched controls—18 males and 12 females, 108 average age 56.7 \pm 10.1 years, all meeting specific criteria for glucose 109 tolerance. Exclusion criteria were a prior diabetes diagnosis, serious 110 concurrent conditions, pregnancy, and dropout from follow-up. Comparisons 111 between baseline data of the two groups showed no significant differences ($P >$ ¹¹²0.05), confirming their comparability. Preliminary results indicate significantly 113 decreased methylation at several sites within the KCNJ11 promoter in T2DM 114 patients compared to controls, particularly at CpG-471—a site crucial for 115 TCF12 binding—highlighting its potential role in T2DM pathogenesis.

116

¹¹⁷**2. Materials and methods**

¹¹⁸**2.1. Sample collection**

119 After receiving approval from the Institutional Ethics Committee, blood 120 samples were collected from 30 newly diagnosed patients with T2DM at the ¹²¹Department of Endocrinology, Second Affiliated Hospital of Soochow 122 University, and 30 healthy volunteers between November 2022 and 123 November 2023. Samples were drawn from the patients' arm veins using 124 disposable sterile syringes and stored in EDTA-containing tubes to prevent 125 coagulation. Collection occurred after an overnight fast, adhering to the WHO ¹²⁶1999 diagnostic criteria. Patients were informed and voluntarily participated in 127 the study as advised by their physicians.

¹²⁸**2.2. DNA extraction**

129 DNA extraction was performed using the TIANamp Genomic DNA kit (DP304; 130 TIANGEN, Germany) according to the manufacturer's standard procedure. ¹³¹Genomic DNA was isolated from 200 µl of the collected peripheral blood 132 samples. The purity of the DNA samples was assessed by calculating the 133 absorbance ratio at 260 nm to 280 nm using an Invitrogen Nanodrop 134 spectrophotometer. The isolated DNA samples were stored at -80°C for 135 further analysis.

¹³⁶**2.3. McrBC-PCR analysis**

¹³⁷McrBC is a GTP-dependent specific nucleic acid endonuclease that acts on ¹³⁸methylcytosine-containing DNA and does not act on unmethylated DNA[33]. 139 The DNA methylation level of the region upstream of the KCNJ11 transcription 140 start site was detected by McrBC-PCR. McrBC digestion was performed with 141 at least 200 ng of genomic DNA using the McrBC kit (M0272S; NEB) 142 according to the manufacturer's instructions. The same amount of DNA 143 without McrBC digestion was used as a negative control. Primers were 144 designed using Primer3, sequences of primers used for McrBC PCR are listed

145 in Supplementary Table 1, 50ul of the PCR amplification system was used 146 and the products were analyzed by electrophoresis on a 1.5% agarose gel.

¹⁴⁷**2.4. Bisulfite sequencing PCR**(**BSP**)

¹⁴⁸DNA Bisulfite Conversion Kit (E3318S; NEB) was applied to DNA bisulfite 149 modification according to the instructions. The total PCR system was 50 µL, to 150 which 6μL of bisulfate-modified DNA template, 25μL of 2xPCR buffer, 2μL ¹⁵¹each of upstream and downstream primers were added, and the final volume 152 was adjusted to 50µL with double-distilled water. The PCR conditions and 153 setting reaction procedures were as follows: pre-denaturation at 94℃ for 3 ¹⁵⁴min, denaturation at 94℃ for 30s, annealing at 55℃ for 30s, and extension at ¹⁵⁵72℃ for 16s for 35 cycles, and the reaction ended with a final extension at 72℃ 156 for 7 min. The PCR products were electrophoresed in a 2% agarose gel, after 157 which the target fragments were recovered. The pMD18-T vector (6011, 158 TaKaRa) was used for TA clonal ligation, followed by transformation of DH5 α 159 receptor cells. Positive clones were selected and sent to AZENTA for 160 sequencing, and the methylation rate was calculated as the number of 161 methylated cytosine (mC) clones/10 \times 100%. The sequencing results were 162 analyzed online according to Web-based Kismeth software (http://katahdin. 163 Mssm.edu/6ismet/revpage.pl)[34].

¹⁶⁵**2.5. Chromatin immunoprecipitation (ChIP) assay**

¹⁶⁶ChIP assay was used to validate the binding of the transcription factor TCF12 167 to the promoter of the KCNJ11 gene. 293T cells were fixed with formaldehyde, 168 and glycine was added for cross-linking. The samples were then placed on ice 169 and sonicated to isolate DNA. Cell lysates were incubated overnight with 170 antibodies (anti-TCF12 antibody(sc-28364,Santa Cruz Biotechnology) or 171 control IgG) at a dilution of 1:50 and then with protein G-agarose beads ¹⁷²(#3956088, Merck KgaA, Germany) at 4°C overnight. Mouse control IgG

¹⁷³(#3452481, Merck KgaA, Germany) was used as a negative control for the 174 reaction. The bound DNA-protein mixture was eluted and the cross-linking 175 was reversed after several washes. The DNA fragments were then purified 176 and subjected to PCR with the KCNJ11 primer. The PCR products (172 bp) 177 were separated on a 2% agarose gel and visualized on a UV transilluminator.

178

¹⁷⁹**2.6. Bioinformatic analysis**

180 Short reads downloaded from the SRA database with accession SRP274496 ¹⁸¹were used to produce quality control reports through FastQC (https://www.bioi 182 nformatics.babraham.ac.uk/projects/fastqc/) and subjected to low-quality filteri 183 ng and adapter trimming using EtoKi (https://pubmed.ncbi.nlm.nih.gov/318092 184 $\frac{57}{\cdot}$. Clean data were aligned to the reference genome using Hisat2 (https://p 185 ubmed.ncbi.nlm.nih.gov/31375807/), and the mapped results were sorted usin 186 g Samtools (https://pubmed.ncbi.nlm.nih.gov/19505943/). Transcriptome asse ¹⁸⁷mbly and counting were carried out using StringTie (https://pubmed.ncbi.nlm.n 188 ih.gov/25690850/). Bioinformatic analysis was performed using the R comman 189 d line, and differential expression analysis was conducted using edgeR (https: 190 //pubmed.ncbi.nlm.nih.gov/19910308/). R packages pheatmap (https://cran.r-191 project.org/web/packages/pheatmap/index.html) were used for visualization.

¹⁹³**2.7. Quantitative real time polymerase chain reaction assay**

194 Peripheral blood leukocyte RNA was extracted with TRIzol TM Reagent ¹⁹⁵(15596026CN, Thermo Fisher Scientific), and reverse transcription was 196 performed according to the instructions of the HiScript II Q RT SuperMix for ¹⁹⁷qPCR(+gDNA wiper)(R223,Vazyme) kit. The total volume of the QPCR 198 amplification mixture was 10μL, and 1μL of cDNA template, 5μL of 2*ChamQ ¹⁹⁹SYBR qPCR Master Mix (Q341,Vazyme,), and 0.2μL of upstream and 200 downstream primers were added. The volume was adjusted to a final volume 201 of 10_μL with double-distilled water. The PCR conditions and the setup of the

202 reaction program were as follows: pre-denaturation at $95 \degree C$ for 180s,

- 203 denaturation at 95℃ for 15s, and annealing and extension at 60°C for 60s,
- 204 and the reaction was run for 39 cycles.
- 205

²⁰⁶**2.8. Statistical analysis**

207 The data are presented as the mean \pm SD. Differences in mean values 208 between two groups were analyzed using the two-tailed t-test. Statistical 209 analyses were performed using the GraphPad Prism version 6.0 (GraphPad 210 Software, USA). *p < 0.05, **p < 0.01, ***p < 0.001 or ****p < 0.0001 were 211 considered statistically significant.

²¹³**3. Results**

214

²¹⁵**3.1. Clinical characteristics of the study population**

216 To maintain a consistent genetic background and characterize the course of 217 the disease, several potential confounders were considered in this study 218 based on the literature and clinical judgment. Covariates included age, sex, 219 body mass index, smoking status, alcohol consumption status, family history, 220 physical activity, creatinine, total cholesterol, triglyceride, and low-density 221 lipoprotein levels of the included subjects. The data included in this study 222 were categorized into two types of continuous and categorical variables. 223 Continuous variables are expressed as the mean \pm standard deviation and ²²⁴were subjected to t-test (normal distribution) or Kruskal-Wallis rank sum test 225 (non-normal distribution) depending on the normality of the distribution; 226 categorical variables were expressed as percentages and were subjected to ²²⁷the χ2 test (**Table 1**). The subjects were divided into a healthy control group 228 and a first-onset type 2 diabetes group according to the WHO 1999 diabetes 229 diagnostic criteria. After the application of strict inclusion criteria, Table 1 230 shows that the differences between the two groups were statistically

231 significant only for fasting blood glucose, two-hour postprandial blood glucose,

232 and glycosylated hemoglobin($P < 0.001$).

233

²³⁴**3.2. McrBC-PCR analysis**

235 Agarose gel electrophoresis of the PCR products of diabetic and healthy 236 control samples with the same amount of DNA before and after 1h of McrBC ²³⁷digestion and analysis of gray values are shown in (**Fig. 1**). The results 238 demonstrated that DNA methylation modification exists in the promoter region 239 of the KCNJ11 gene in patients with first-onset T2DM and healthy controls, 240 and that the degree of methylation modification in healthy control samples is 241 likely to be greater than that in patients with first-onset T2DM.

242

²⁴³**3.3. BSP results confirm differences in site-specific methylation of the** ²⁴⁴**KCNJ11 promoter region between healthy controls and patients with** ²⁴⁵**first-onset T2DM**

²⁴⁶We analyzed DNA methylation at selected locations in this region in the 247 healthy and T2DM groups using the bisulfite sequencing method, as shown in 248 Figure 2B, and the results based on Kismeth software analysis showed an 249 overall decrease in cytosine methylation levels from 22.22% to 3.33%.

250

251 Moreover, after bisulfite modification treatment and sequencing of positive 252 clones, it was demonstrated that there were methylation sites at nine sites, including CpG-449, CpG-454, CpG-471, CpG-499, CpG-504, CpG-510, CpG-513, CpG-520, and CpG-539.The methylation ratios of the above loci were 255 significantly lower in patients in the type 2 diabetes group, whereas they were hypermethylated in the healthy normal control group. Moreover, at the CpG-471 locus, the methylation rate was decreased by approximately 7.55% in the T2DM group compared with that in the healthy control group **(Fig. 2C)**.

²⁶⁰**3.4. Binding of differentially methylated sites in the promoter region of**

²⁶¹**the KCNJ11 gene to the transcription factor TCF12**

262 DNA methylation has been extensively studied over the past few decades, 263 and the attachment of methyl groups to the promoter region of a gene might 264 inhibit transcription factor binding, and hence usually reduce transcription; the 265 opposite phenomenon also holds true[35, 36]. The results analyzed by ²⁶⁶JASPAR and AlphaFold online software showed that the presence of TCF12 267 transcription factor binds to the promoter region of the KCNJ11 gene near the 268 differentially methylated site CpG-471, which may explain the ²⁶⁹hypomethylation of the KCNJ11 promoter region in patients with T2DM, which 270 can affect protein expression by enhancing the activity of the transcription 271 factor TCF12 and thus predispose them to developing T2DM **(Fig. 3A)**. CHIP-272 PCR gel electrophoresis revealed target bands in the input group and anti-²⁷³TCF12 group but no bands in the IgG or blank group **(Fig. 3B)**, which also 274 confirmed that the transcription factor TCF12 binds to the promoter region of 275 the KCNJ11 gene and may be involved in the methylation changes at specific 276 loci of the KCNJ11 gene, possibly influencing the regulatory pathways 277 involved in pancreatic beta-cell function.

278

²⁷⁹**3.5. KCNJ11 expression in human peripheral blood**

280 The RNA-seq data from 12 blood samples obtained from the SRA database, 281 including 6 from healthy individuals and 6 from type 2 diabetes patients, were 282 included in the analysis. Differential gene expression analysis revealed that 283 the KCNJ11 gene was upregulated in the type 2 diabetes group (logFC = ²⁸⁴1.478151, p = 0.09869249, FDR = 0.3574878) **(Fig. 4A)**. We then extracted ²⁸⁵RNA from fresh peripheral blood of enrolled healthy controls and T2DM 286 patients for semi-quantitative analysis of the KCNJ11 gene, and the results 287 demonstrated that KCNJ11 mRNA expression was increased in peripheral ²⁸⁸blood from patients with T2DM compared with that in peripheral blood from ²⁸⁹healthy controls (p < 0.001) **(Fig. 4B)**.

290

²⁹¹**4. Discussion**

292 In this study, BSP-sequencing was utilized to examine methylation levels at 293 specific sites within the KCNJ11 gene promoter in blood samples from 294 individuals at the early stages of Type 2 Diabetes Mellitus (T2DM). Employing 295 bisulfite conversion, a well-established technique for DNA cytosine ²⁹⁶methylation analysis[37], our results demonstrated distinct differences in 297 methylation patterns at several critical sites between newly diagnosed T2DM 298 patients and healthy controls.

²⁹⁹The current literature establishes a clear link between DNA methylation at ³⁰⁰gene promoters, CpG islands, and proximal gene body sites with changes in 301 transcriptional activity and gene expression[38, 39]. Our findings reinforce this 302 paradigm, revealing significant hypomethylation at pivotal sites within the ³⁰³KCNJ11 promoter in T2DM subjects. This epigenetic alteration likely facilitates 304 increased binding of the transcription factor TCF12, potentially augmenting 305 protein expression and, consequently, T2DM susceptibility. This observation 306 underscores the therapeutic potential of targeting TCF12, not only enhancing 307 our understanding of its regulatory mechanisms but also promoting it as a 308 viable target for T2DM treatment.

³⁰⁹Research within the diabetes field is predominantly focused on two 310 approaches: comprehensive scans for differential DNA methylation across the ³¹¹genome[40] and targeted investigations into known diabetes-associated 312 genes using specific primers to pinpoint differential methylation [15, 16, 41, 42]. 313 Our study's focus on the KCNJ11 promoter methylation contributes 314 significantly to the broader epigenetic narrative of T2DM pathogenesis, paving 315 the way for novel insights into disease mechanisms and therapeutic 316 innovation[43]. The role of methylation in other gene loci related to diabetes 317 progression remains an open question warranting further exploration.

³¹⁸With diabetes prevalence increasing globally, the imperative for innovative 319 therapeutic approaches is more pressing than ever. Future treatment ³²⁰modalities might include epigenetic editing of specific genes[44], a strategy 321 supported by emerging research advocating for targeting the enzymes that ³²²modify epigenetic landscapes in tissues affected by diabetes[45, 46]. ³²³Moreover, epigenetic changes in diabetic patients have been increasingly 324 associated with severe vascular complications, such as retinopathy, stroke, 325 and myocardial infarction[47-49]. Identifying epigenetic biomarkers, readily 326 detectable in blood and derivative from target tissues, could profoundly impact 327 clinical practices by facilitating easier analysis in diabetic and at-risk 328 populations. However, the discovery of epigenetic markers with superior 329 predictive strength over existing diabetes indicators remains a critical 330 research need.

331 In summary, our study has identified significant epigenetic modifications in the 332 promoter of the KCNJ11 gene in patients with T2DM, highlighting a robust link ³³³between epigenetics and the pathophysiology of diabetes in humans. These ³³⁴epigenetic markers offer promising avenues as biomarkers for predicting 335 T2DM, gauging the risk of vascular complications, and assessing the efficacy 336 of therapeutic and lifestyle interventions, thus heralding a new era of precision 337 medicine in diabetes care.

³³⁸**Acknowledgements**

³³⁹This research was supported by grants from the National Natural Science ³⁴⁰Foundation of China (82371544,82070814); Suzhou Healthcare Science and 341 Technology Innovation Program (SKYD2022030); Open project of Jiangsu 342 Health Development Research Center (JSHD2022035); A Project Funded by 343 the Priority Academic Program Development of Jiangsu Higher Education 344 Institutions.

³⁴⁵**Conflict of interest**

346 None declared.

434 [25]. Gloyn AL, Pearson ER, Antcliff JF, Proks P, Bruining GJ, Slingerland AS,
435 **et al. Activating mutations in the gene encoding the ATP-sensitive potass** et al. Activating mutations in the gene encoding the ATP-sensitive potassi
436 **Four-metal and in the ATP-sensitive State** 11 am-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J M 436 um-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J M
437 ed. 2004;350:1838-49.http://dx.doi.org/10.1056/NEJMoa032922 ⁴³⁷ed. 2004;350:1838-49.http://dx.doi.org/10.1056/NEJMoa032922 438 [26]. Schwanstecher C, Meyer U, Schwanstecher M. K(IR)6.2 polymorphism p
439 fedisposes to type 2 diabetes by inducing overactivity of pancreatic beta-439 redisposes to type 2 diabetes by inducing overactivity of pancreatic beta-
440 cell ATP-sensitive K(+) channels. Diabetes. 2002:51:875-9.http://dx.doi.or ⁴⁴⁰cell ATP-sensitive K(+) channels. Diabetes. 2002;51:875-9.http://dx.doi.or 441 g/10.2337/diabetes.51.3.875
442 [27]. Schwanstecher C. Neugeba 442 [27]. Schwanstecher C, Neugebauer B, Schulz M, Schwanstecher M. The co
443 mmon single nucleotide polymorphism E23K in K(IR)6.2 sensitizes pancr 443 mmon single nucleotide polymorphism E23K in K(IR)6.2 sensitizes pancr
444 eatic beta-cell ATP-sensitive potassium channels toward activation throug eatic beta-cell ATP-sensitive potassium channels toward activation throug
445 h nucleoside diphosphates. Diabetes. 2002:51 Suppl 3:S363-7.http://dx.d 445 h nucleoside diphosphates. Diabetes. 2002;51 Suppl 3:S363-7.http://dx.d
446 oi.org/10.2337/diabetes.51.2007.s363 446 oi.org/10.2337/diabetes.51.2007.s363
447 [28]. Fuiita PA. Rhead B. Zweig AS. Hinrich 447 [28]. Fujita PA, Rhead B, Zweig AS, Hinrichs AS, Karolchik D, Cline MS, et al.
448 The UCSC Genome Browser database: update 2011. Nucleic Acids Res. 448 The UCSC Genome Browser database: update 2011. Nucleic Acids Res.
449 2011:39:D876-82.http://dx.doi.org/10.1093/nar/gkg963 ⁴⁴⁹2011;39:D876-82.http://dx.doi.org/10.1093/nar/gkq963 450 [29]. Elliott HR, Walia GK, Duggirala A, Groom A, Reddy SU, Chandak GR, et
451 **1998** al. Migration and DNA methylation: a comparison of methylation patterns i al. Migration and DNA methylation: a comparison of methylation patterns i
452 htvpe 2 diabetes susceptibility genes between indians and europeans. J 452 httpe 2 diabetes susceptibility genes between indians and europeans. J
453 **http://dx.doi.org/10.7243/2050-0866-2** Diabetes Res Clin Metab. 2013;2:6.http://dx.doi.org/10.7243/2050-0866-2
-6 454
455 455 [30]. Bacos K, Gillberg L, Volkov P, Olsson AH, Hansen T, Pedersen O, et al.
456 Blood-based biomarkers of age-associated epigenetic changes in human 456 Blood-based biomarkers of age-associated epigenetic changes in human
457 islets associate with insulin secretion and diabetes. Nat Commun. 2016;7 457 islets associate with insulin secretion and diabetes. Nat Commun. 2016;7:
458 11089.http://dx.doi.org/10.1038/ncomms11089 458 11089.<u>http://dx.doi.org/10.1038/ncomms11089</u>
159 I311. Bvsani M. Perfilvev A. de Mello VD. Ronn T. N 459 [31]. Bysani M, Perfilyev A, de Mello VD, Ronn T, Nilsson E, Pihlajamaki J, et
460 **1988** al. Epigenetic alterations in blood mirror age-associated DNA methylation 460 al. Epigenetic alterations in blood mirror age-associated DNA methylation
461 and gene expression changes in human liver. Epigenomics. 2017:9:105-461 and gene expression changes in human liver. Epigenomics. 2017;9:105-462
462 22.http://dx.doi.org/10.2217/epi-2016-0087 ⁴⁶²22.http://dx.doi.org/10.2217/epi-2016-0087 463 [32]. Ronn T, Volkov P, Gillberg L, Kokosar M, Perfilyev A, Jacobsen AL, et al.
464 **Impact of age, BMI and HbA1c levels on the genome-wide DNA methylat** 464 Impact of age, BMI and HbA1c levels on the genome-wide DNA methylati
465 on and mRNA expression patterns in human adipose tissue and identifica 465 on and mRNA expression patterns in human adipose tissue and identifica
466 tion of epigenetic biomarkers in blood. Hum Mol Genet. 2015;24:3792-81 466 tion of epigenetic biomarkers in blood. Hum Mol Genet. 2015;24:3792-81
467 3.http://dx.doi.org/10.1093/hmg/ddv124 467 3.http://dx.doi.org/10.1093/hmg/ddv124
468 [33]. Sutherland E. Coe L. Raleigh EA. McrE 468 [33]. Sutherland E, Coe L, Raleigh EA. McrBC: a multisubunit GTP-dependent
469 **1992:225:327-48.http://dx.doi.org/1** 469 restriction endonuclease. J Mol Biol. 1992;225:327-48.http://dx.doi.org/1
470 0.1016/0022-2836(92)90925-a 470 0.1016/0022-2836(92)90925-a
171 [34]. Gruntman E, Qi Y, Slotkin RK, 471 [34]. Gruntman E, Qi Y, Slotkin RK, Roeder T, Martienssen RA, Sachidananda
472 m R. Kismeth: analyzer of plant methylation states through bisulfite seque 472 m R. Kismeth: analyzer of plant methylation states through bisulfite seque
473 http://dx.doi.org/10.1186/1471-21 473 ncing. BMC Bioinformatics. 2008;9:371.http://dx.doi.org/10.1186/1471-21
474 05-9-371 ⁴⁷⁴05-9-371 475 [35]. Volkov P, Bacos K, Ofori JK, Esguerra JL, Eliasson L, Ronn T, et al. Whol
476 **1998 - Le Contain Bulle Seguencing of Human Pancreatic Islets Reveals Nov** 476 e-Genome Bisulfite Sequencing of Human Pancreatic Islets Reveals Nov
477 el Differentially Methylated Regions in Type 2 Diabetes Pathogenesis. Dia ⁴⁷⁷el Differentially Methylated Regions in Type 2 Diabetes Pathogenesis. Dia

576 glucose; PBG – postprandial blood glucose; Scr – serum creatinine; TG –

 577 triglyceride; TC – serum total cholesterol; LDL-C – low-density lipoprotein

- 578 cholesterol; p statistical significance.
-
- 580
- 582

582

583

585 585

- 587
- 588
- 588
- 589 591
- 592

592

593

595

595 $\frac{1}{567}$

602 on the left side is the uncut control, and on the right side is the digestion 603 for 1h (A); The below panel shows the bar graph of gray value analysis (B). 604 Abbreviations: $U -$ undigested; M – McrBC digested; P – patient; C – 605 healthy control.

598

-
- 608
-

FIG. 2.

(A). KCNJ11 mRNA expression levels in human peripheral blood from

- 695 healthy controls and patients with T2DM. Gene expression was analyzed
- 696 using quantitative RT-PCR. The results are expressed as the mean \pm SD
- ⁶⁹⁷(B).